drugset / Trial / NCT06773481
BC008-1A Injection for Recurrent CNS WHO G4 Glioma
Phase 1
Recruiting
40 enrolled
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
Beijing Tiantan Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this Phase I clinical study is to evaluate the safety, preliminary efficacy and pharmacokinetic characteristics of BC008-1A injection in subjects with recurrent CNS WHO grade 4 glioma. This is a randomized and open-label study, with two dose groups set up, and 10 to 20 subjects will be enrolled in each group.
Timeline
- Start
- 2025-04-07
- Primary completion
- 2026-06
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BC008-1A | Unknown | 900 mg | Intravenous |
| Subject | BC008-1A | Unknown | 1200 mg | Intravenous |